Modeling Best Practices of Medically Integrated Pharmacies to Improve Treatment Monitoring and Therapy Adherence in Patients with HR+/HER2- Breast Cancer

Modeling Best Practices of Medically Integrated Pharmacies to Improve Treatment Monitoring and Therapy Adherence in Patients With HR+/HER2- Breast Cancer

Train the Trainer

Pharmacists are involved in all phases of a patient’s cancer journey and their role continues to expand in response to the rapid pace of therapeutic advances. This evolving role is especially critical in the complex treatment of patients with HR+/HER2- metastatic breast cancer. Availability of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors has shifted the treatment paradigm but identification of which patients may benefit from particular CDK4/6 inhibitors must consider assessment of a patient’s ability to tolerate treatment-related adverse events (AEs) and continue therapy.

To meet this need, evolving interprofessional approaches to patient care offer proven methods for monitoring and managing AEs, improving therapy access, and further supporting personalized care; however, for more patients to realize the benefits of this approach, comprehensive training is needed to ensure pharmacists, employed in a variety of settings, can perform integrated care functions. This training program offers pharmacists the education, tools, and resources necessary to model best practices of medically integrated pharmacies and improve outcomes for patients with HR+/HER2- metastatic breast cancer. Upon completion of the training program, pharmacists can customize a curriculum to facilitate peer-to-peer learning and action planning with their own team, considerate of the size and resource mix of their practice.

Faculty: Scott Soefje, PharmD; Jodi Taraba, PharmD

Release Date: February 28, 2025

Expiration Date: February 28, 2026